Molecular cancer prevention: Current status and future directions

CA Cancer Journal for Clinicians

Volumn 65, Issue 5, 2015, Pages 345-383

  Maresso, Karen Colbert ^a   Tsai, Kenneth Y ^b   Brown, Powel H ^a   Szabo, Eva ^c   Lippman, Scott ^d   Hawk, Ernest T ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

chemoprevention; molecular prevention; prevention; randomized controlled trial

Indexed keywords

AMINOLEVULINIC ACID; ANASTROZOLE; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ARZOXIFENE; BCG VACCINE; BIOLOGICAL MARKER; CELECOXIB; DICLOFENAC; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FENRETINIDE; FLUOROURACIL; HEPATITIS B VACCINE; IMIQUIMOD; INGENOL MEBUTATE; INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; NUCLEOSIDE ANALOG; PHOTOFRIN; PLACEBO; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNINDEXED DRUG; VALRUBICIN; WART VIRUS VACCINE;

ACCREDITATION; ACTINIC KERATOSIS; ARTICLE; BARRETT ESOPHAGUS; BLADDER CANCER; BLADDER PAPILLOMA; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CARCINOGENESIS; CARCINOMA IN SITU; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL POLYP; COST EFFECTIVENESS ANALYSIS; CYSTECTOMY; DEEP VEIN THROMBOSIS; DISEASE ERADICATION; DNA DAMAGE; DNA DETERMINATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPLASIA; EARLY DIAGNOSIS; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENETIC HETEROGENEITY; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HELICOBACTER PYLORI; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HETEROZYGOSITY LOSS; HIGH RISK POPULATION; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MEDICAL EDUCATION; MELANOMA; MOLECULAR PREVENTION; NON MELANOMA SKIN CANCER; NON MUSCLE INVASIVE BLADDER CANCER; NONHODGKIN LYMPHOMA; NURSING EDUCATION; PAPANICOLAOU TEST; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SCHISTOSOMIASIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; SKIN CARCINOMA; STOMACH CANCER; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; URINARY BLADDER CARCINOMA IN SITU; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERUS CANCER; VAGINA DISCHARGE; VAGINAL DRYNESS; VERRUCA VULGARIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 84941599229     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21287     Document Type: Article

References (316)

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW,. Cancer genome landscapes. Science. 2013; 339: 1546-1558.
2. Sporn MB, Dunlop NM, Newton DL, Smith JM,. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976; 35: 1332-1338.
3. Chou R, Dana T, Bougatsos C, Blazina I, Khangura J, Zakher B,. Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the US Preventive Services Task Force recommendation. Ann Intern Med. 2014; 161: 31-45.
4. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R,. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med. 2013; 158: 114-123.
5. HIV-CAUSAL Collaboration, Ray M, Logan R, et al., The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010; 24: 123-137.
6. Graham DY, Lee YC, Wu MS,. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence [serial online]. Clin Gastroenterol Hepatol. 2014; 12: 177-186.e3; discussion 186.e12-186.e73.
7. Kramer CV, Zhang F, Sinclair D, Olliaro PL,. Drugs for treating urinary schistosomiasis [serial online]. Cochrane Database Syst Rev. 2014; 8: CD000053.
8. Veronesi U, De Palo G, Costa A, Formelli F, Decensi A., Chemoprevention of breast cancer with fenretinide. IARC Sci Publ. 1996: 87-94.
9. Veronesi U, De Palo G, Marubini E, et al., Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999; 91: 1847-1856.
10. Fisher B, Costantino JP, Wickerham DL, et al., Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90; 1371-1383.
11. Fisher B, Costantino JP, Wickerham DL, et al., Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005; 97: 1652-1662.
12. Powles T, Eeles R, Ashley S, et al., Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 1998. 352: 98-101.
13. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M,. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007; 99: 283-290.
14. Veronesi U, Maisonneuve P, Costa A, et al., Prevention of breast cancer with tamoxifen; preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998; 352: 93-97.
15. Veronesi U, Maisonneuve P, Rotmensz N, et al., Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007; 99: 727-737.
16. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet. 2002; 360: 817-824.
17. Cuzick J, Forbes JF, Sestak I, et al., Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007; 99: 272-282.
18. Vogel VG, Costantino JP, Wickerham DL, et al., Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295: 2727-2741.
19. Vogel VG, Costantino JP, Wickerham DL, et al., Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010; 3: 696-706.
20. Cummings SR, Eckert S, Krueger KA, et al., The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999; 281: 2189-2197.
21. Cauley JA, Norton L, Lippman ME, et al., Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat. 2001; 65: 125-134.
22. Martino S, Cauley JA, Barrett-Connor E, et al., Continuing outcomes relevant to Evista: Breast Cancer Incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004; 96: 1751-1761.
23. Barrett-Connor E, Mosca L, Collins P, et al., Effects of raloxifine on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355: 125-137.
24. LaCroix AZ, Powles T, Osborne CK, et al., Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010; 102: 1706-1715.
25. Cummings SR, Ensrud K, Delmas PD, et al., Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010; 362: 686-696.
26. Cummings SR, McClung M, Reginster JY, et al., Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011; 26: 397-404.
27. Powles TJ, Diem SJ, Fabian CJ, et al., Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat. 2012;134:299-306.
28. Cuzick J,. IBIS II. A breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 2008; 8: 1377-1385.
29. Cuzick J, Sestak I, Forbes JF, et al., Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014; 383: 1041-1048.
30. Goss PE, Ingle JN, Ales-Martinez JE, et al., Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011; 364: 2381-2391.
31. Meyskens FL Jr, Gilmartin E, Alberts DS, et al., Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst. 1994; 86: 539-543.
32. Childers JM, Chu J, Voigt LF, et al., Chemoprevention of cervical cancer with folic acid: a phase III Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev. 1995; 4: 155-159.
33. Koutsky LA, Ault KA, Wheeler CM, et al., A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347: 1645-1651.
34. Alvarez RD, Conner MG, Weiss H, et al., The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol Biomarkers Prev. 2003; 12: 114-119.
35. Ruffin MT, Bailey JM, Normolle DP, et al., Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer Epidemiol Biomarkers Prev. 2004; 13: 2148-2152.
36. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 1915-1927.
37. Munoz N, Wharendorf J, Bang LJ, et al., No effect of riboflavin, retinol, and zinc on prevalence of precancerous lesions of oesophagus. Randomized double-blind intervention study in high-risk population of China. Lancet. 1985; 2: 111-114.
38. Munoz N, Hayashi M, Bang LJ, Wahrendorf J, Crespi M, Bosch FX,. Effect of riboflavin, retinol, and zinc on micronuclei of buccal mucosa and of esophagus: a randomized double-blind intervention study in China. J Natl Cancer Inst. 1987; 79: 687-691.
39. Blot WJ, Li JY, Taylor PR, et al., Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993; 85: 1483-1492.
40. Qiao YL, Dawsey SM, Kamangar F, et al., Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst. 2009; 101: 507-518.
41. Li JY, Taylor PR, Li B, et al., Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst. 1993; 85: 1492-1498.
42. Wang JB, Abnet CC, Fan JH, Qiao YL, Taylor PR,. The randomized Linxian Dysplasia Nutrition Intervention Trial after 26 years of follow-up: no effect of multivitamin supplementation on mortality. JAMA Intern Med. 2013; 173: 1259-1261.
43. Limburg PJ, Wei W, Ahnen DJ, et al., Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology. 2005; 129: 863-873.
44. Axcan Pharma US Inc. PHOTOFRIN-porfimer sodium injection [package insert]. Birmingham, AL: Axcan Pharma US Inc.; 2003.
45. Heath EI, Canto MI, Piantadosi S, et al., Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007; 99: 545-557.
46. Labayle D, Fischer D, Vielh P, et al., Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991; 101: 635-639.
47. Giardiello FM, Hamilton SR, Krush AJ, et al., Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993; 328: 1313-1316.
48. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK,. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993; 80: 1618-1619.
49. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH,. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993; 85: 1220-1224.
50. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH,. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med. 1998; 128: 713-720.
51. Steinbach G, Lynch PM, Phillips RK, et al., The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000; 342: 1946-1952.
52. Giardiello FM, Yang VW, Hylind LM, et al., Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002; 346: 1054-1059.
53. Baron JA, Cole BF, Sandler RS, et al., A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003; 348: 891-899.
54. Sandler RS, Halabi S, Baron JA, et al., A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003; 348: 883-890.
55. Benamouzig R, Deyra J, Martin A, et al., Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003; 125: 328-336.
56. Benamouzig R, Uzzan B, Deyra J, et al., Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut. 2012; 61: 255-261.
57. Cook NR, Lee IM, Gaziano JM, et al., Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294: 47-55.
58. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE,. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013; 159: 77-85.
59. Arber N, Eagle CJ, Spicak J, et al., Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006; 355: 885-895.
60. Bertagnolli MM, Eagle CJ, Zauber AG, et al., Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006; 355: 873-884.
61. Flossmann E, Rothwell PM,. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369: 1603-1613.
62. Meyskens FL Jr, McLaren CE, Pelot D,. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized PlaceboControlled, Double-Blind Trial. Cancer Prev Res (Phila). 2008; 1: 32-38.
63. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR,; ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008; 134: 29-38.
64. Rothwell PM, Wilson M, Elwin CE, et al., Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010; 376: 1741-1750.
65. Burn J, Bishop DT, Chapman PD, et al., A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011; 4: 655-665.
66. Burn J, Gerdes AM, Macrae F, et al., Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011; 378: 2081-2087.
67. Hulley S, Furberg C, Barrett-Connor E, et al., Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 58-66.
68. Rossouw JE, Anderson GL, Prentice RL, et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333.
69. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al., Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004; 350: 991-1004.
70. Anderson GL, Limacher M, Assaf AR, et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701-1712.
71. Ritenbaugh C, Stanford JL, Wu L, et al., Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2609-2618.
72. Greenberg ER, Baron JA, Tosteson TD, et al., A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med. 1994; 331: 141-147.
73. MacLennan R, Macrae F, Bain C, et al., Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst. 1995; 87: 1760-1766.
74. Clark LC, Combs GF Jr, Turnbull BW, et al., Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996; 276: 1957-1963.
75. Baron JA, Beach M, Mandel JS, et al., Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med. 1999; 340: 101-107.
76. Alberts DS, Martinez ME, Roe DJ, et al., Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med. 2000; 342: 1156-1162.
77. Schatzkin A, Lanza E, Corle D, et al., Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med. 2000; 342: 1149-1155.
78. Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J., Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet. 2000; 356: 1300-1306.
79. Wactawski-Wende J, Kotchen JM, Anderson GL, et al., Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006; 354: 684-696.
80. Lippman SM, Klein EA, Goodman PJ, et al., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009; 301: 39-51.
81. West NJ, Clark SK, Phillips RKS, et al., Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut. 2010; 59: 918-925.
82. Baron JA, Barry EL, Ahnen DJ, et al., A clinical trial of supplementation with vitamin D and/or calcium for the prevention of colorectal adenomas [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; April 5-9, 2014; San Diego, CA. Cancer Res. 2014; 74 (19 suppl). Abstract CT335.
83. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM,. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980; 124: 38-40.
84. Pinsky CM, Camacho FJ, Kerr D, et al., Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep. 1985; 69: 47-53.
85. Herr HW, Laudone VP, Badalament RA, et al., Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol. 1988; 6: 1450-1455.
86. Herr HW, Schwalb DM, Zhang ZF, et al., Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol. 1995; 13: 1404-1408.
87. Lamm DL, Blumenstein BA, Crissman JD, et al., Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000; 163: 1124-1129.
88. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M,. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000; 163: 761-767.
89. Dinney CP, Greenberg RE, Steinberg GD,. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol. 2013; 31: 1635-1642.
90. Greenberg ER, Baron JA, Stukel TA, et al., A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med. 1990; 323: 789-795.
91. Tangrea JA, Edwards BK, Taylor PR, et al., Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst. 1992; 84: 328-332.
92. Levine N, Moon TE, Cartmel B, et al., Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997; 6: 957-961.
93. Clark LC, Dalkin B, Krongrad A, et al., Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol. 1998; 81: 730-734.
94. Moon TE, Levine N, Cartmel B, et al., Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997; 6: 949-956.
95. Frieling UM, Schaumberg DA, Kupper TS, Muntwyler J, Hennekens CH., A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study. Arch Dermatol. 2000; 136: 179-184.
96. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P,. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet. 2001; 357: 926-929.
97. Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR., Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol. 2001; 45: 96-104.
98. Jarvis B, Figgitt DP., Topical 3% diclofenac in 2.5% hyaluronic acid gel: a review of its use in patients with actinic keratoses. Am J Clin Dermatol. 2003; 4: 203-213.
99. Bavinck JN, Tieben LM, Van der Woude FJ, et al., Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995; 13: 1933-1938.
100. Lebwohl M, Dinehart S, Whiting D, et al., Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004; 50: 714-721.
101. Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S., Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010; 62: 573-581.
102. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S., Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010; 62: 582-590.
103. Elmets CA, Viner JL, Pentland AP, et al., Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010; 102: 1835-1844.
104. Bailey HH, Kim K, Verma AK, et al., A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of α-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila). 2010; 3: 35-47.
105. Weinstock MA, Bingham SF, Digiovanna JJ, et al., Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): a Veterans Affairs randomized chemoprevention trial. J Invest Dermatol. 2012; 132: 1583-1590.
106. Kadakia KC, Barton DL, Loprinzi CL, et al., Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer. 2012; 118: 2128-2137.
107. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B., Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012; 366: 1010-1019.
108. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al., Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012; 366: 2180-2188.
109. Hong WK, Endicott J, Itri LM, et al., 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986; 315: 1501-1505.
110. Hong WK, Lippman SM, Itri LM, et al., Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990; 323: 795-801.
111. Lippman SM, Batsakis JG, Toth BB, et al., Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993; 328: 15-20.
112. Khuri FR, Lee JJ, Lippman SM, et al., Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006; 98: 441-450.
113. Bolla M, Lefur R, Ton Van J, et al., Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer. 1994; 30A: 767-772.
114. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H., EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst. 2000; 92: 977-986.
115. Papadimitrakopoulou VA, Lee JJ, William WN Jr, et al., Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009; 27: 599-604.
116. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994; 330: 1029-1035.
117. Virtamo J, Pietinen P, Huttunen JK, et al., Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA. 2003; 290: 476-485.
118. Omenn GS, Goodman GE, Thornquist MD, et al., Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996; 334: 1150-1155.
119. Hennekens CH, Buring JE, Manson JE, et al., Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996; 334: 1145-1149.
120. Lippman SM, Lee JJ, Karp DD, et al., Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001; 93: 605-618.
121. Karp DD, Lee SJ, Keller SM, et al., Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol. 2013; 31: 4179-4187.
122. Thompson IM, Goodman PJ, Tangen CM, et al., The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349: 215-224.
123. Klein EA, Thompson IM Jr, Tangen CM, et al., Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011; 306: 1549-1556.
124. Andriole GL, Bostwick DG, Brawley OW, et al., Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362: 1192-1202.
125. Correa P, Fontham ET, Bravo JC, et al., Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst. 2000; 92: 1881-1888.
126. Wong BC, Lam SK, Wong WM, et al., Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004; 291: 187-194.
127. You WC, Brown LM, Zhang L, et al., Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006; 98: 974-983.
128. Ma JL, Zhang L, Brown LM, et al., Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012; 104: 488-492.
129. Wong BC, Zhang L, Ma JL, et al., Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012; 61: 812-818.
130. Nishiguchi S, Kuroki T, Nakatani S, et al., Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346: 1051-1055.
131. Muto Y, Moriwaki H, Ninomiya M, et al., Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996; 334: 1561-1567.
132. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF,. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999; 29: 971-975.
133. Valla DC, Chevallier M, Marcellin P, et al., Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999; 29: 1870-1875.
134. Liaw YF, Sung JJ, Chow WC, et al., Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351: 1521-1531.
135. Gaziano JM, Sesso HD, Christen WG, et al., Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2012; 308: 1871-1880.
136. Sporn MB, Liby KT,. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat Clin Pract Oncol. 2005; 2: 518-525.
137. Sporn MB, Suh N,. Chemoprevention of cancer. Carcinogenesis. 2000; 21: 525-530.
138. Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res. 1999; 59: 4743-4758.
139. Meyskens FL, Curt GA, Brenner DE, et al., Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila). 2011; 4: 311-323.
140. Kelly RJ, Lopez-Chavez A, Szabo E,. Criteria of evidence to move potential chemopreventive agents into late phase clinical trials. Curr Drug Targets. 2011; 12: 1983-1988.
141. Kelloff GJ, Lippman SM, Dannenberg AJ, et al., Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res. 2006; 12: 3661-3697.
142. Phillips RK, Wallace MH, Lynch PM, et al., A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002; 50: 857-860.
143. Lazzeroni M, Serrano D, Dunn BK, et al., Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug [serial online]. Breast Cancer Res. 2012; 14: 214.
144. Vogel VG, Qu Y, Wong M, Mitchell B, Mershon JL,. Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration. Clin Breast Cancer. 2009; 9: 45-50.
145. Grady D, Cauley JA, Geiger MJ, et al., Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst. 2008; 100: 854-861.
146. Cuzick J, Sestak I, Bonanni B, et al., Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013; 381: 1827-1834.
147. Cuzick J, Sestak I, Cawthorn S, et al., Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015; 16: 67-75.
148. Baum M, Budzar AU, Cuzick J, et al., Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359: 2131-2139.
149. Cuzick J, Sestak I, Baum M, et al., Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010; 11: 1135-1141.
150. Kuerer HM, Buzdar AU, Mittendorf EA, et al., Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011; 117: 39-47.
151. Strecker TE, Shen Q, Zhang Y, et al., Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009; 101: 107-113.
152. Decensi A, Puntoni M, Pruneri G, et al., Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila). 2011; 4: 1181-1189.
153. Harris RE, Alshafie GA, Abou-Issa H, Seibert K,. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000; 60: 2101-2103.
154. Howe LR, Subbaramaiah K, Patel J, et al., Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002; 62: 5405-5407.
155. Anzano MA, Byers SW, Smith JM, et al., Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 1994; 54: 4614-4617.
156. Wu K, Kim HT, Rodriquez JL, et al., 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res. 2000; 6: 3696-3704.
157. Campbell MJ, Esserman LJ, Zhou Y, et al., Breast cancer growth prevention by statins. Cancer Res. 2006; 66: 8707-8714.
158. Garwood ER, Kumar AS, Baehner FL, et al., Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010; 119: 137-144.
159. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ,. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1028-1033.
160. Crew KD, Brown P, Greenlee H, et al., Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012; 5: 1144-1154.
161. Xue F, Michels KB,. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr. 2007; 86: s823-s835.
162. Niraula S, Dowling RJ, Ennis M, et al., Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. 2012; 135: 821-830.
163. Bonanni B, Puntoni M, Cazzaniga M, et al., Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012; 30: 2593-2600.
164. Baron JA, Sandler RS, Bresalier RS, et al., Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008; 372: 1756-1764.
165. Graham DJ, Campen D, Hui R, et al., Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005; 365: 475-481.
166. Kerr DJ, Dunn JA, Langman MJ, et al., Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med. 2007; 357: 360-369.
167. Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM,. Persistence of cardiovascular risk after rofecoxib discontinuation. Arch Intern Med. 2010; 170: 2035-2036.
168. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al., Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011; 123: 2226-2235.
169. Nelson HD, Smith ME, Griffin JC, Fu R,. Use of medications to reduce risk for primary breast cancer: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2013; 158: 604-614.
170. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2014.
171. de Martel C, Ferlay J, Franceschi S, et al., Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13: 607-615.
172. Seoud M, Tjalma WA, Ronsse V,. Cervical adenocarcinoma: moving towards better prevention. Vaccine. 2011; 29: 9148-9158.
173. Trottier H, Franco EL,. The epidemiology of genital human papillomavirus infection. Vaccine. 2006; 24 (suppl 1): S1-S15.
174. Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K,. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the US Preventive Services Task Force. Ann Intern Med. 2011; 155: 698-705, W216.
175. Zell JA, Meyskens FL,. Cancer prevention, screening, and early detection. In:, Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff's Clinical Oncology, 2008. 4th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2008: 361-395.
176. Lacey CJ, Lowndes CM, Shah KV,. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006; 24 (suppl 3): 35-41.
177. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011; 59: 626-629.
178. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011; 60: 1705-1708.
179. US Food and Drug Administration. Vaccines, Blood & Biologics. Cervarix (STN: BL 125259). fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm186957.htm. Accessed October 16, 2009.
180. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, et al., Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009; 374: 1975-1985.
181. Harper DM, Franco EL, Wheeler C, et al., Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004; 364: 1757-1765.
182. Paavonen J, Naud P, Salmeron J, et al., Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374: 301-314.
183. Wheeler CM. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine co-administered with other vaccines in female adolescents [abstract]. Presented at the 47th Annual Meeting of the Infectious Diseases Society of America; Philadelphia, PA: October 29 to November 1, 2009. Abstract LB-43.
184. Descamps D, Hardt K, Spiessens B, et al., Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009; 5: 332-340.
185. Verstraeten T, Descamps D, David MP, et al., Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008; 26: 6630-6638.
186. Moyer VA,. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156: 880-891.
187. Saslow D, Solomon D, Lawson HW, et al., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62: 147-172.
188. Giuliano AR, Palefsky JM, Goldstone S, et al., Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011; 364: 401-411.
189. Markowitz LE, Dunne EF, Saraiya M, et al., Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014; 63: 1-30.
190. US Food and Drug Administration (FDA). FDA Approves Gardasil 9 for Prevention of Certain Cancers Caused by Five Additional Types of HPV. Silver Spring, MD: US Food and Drug Administration; 2014.
191. Merck & Company. Gardasil 9 [package insert]. Whitehouse Station, NJ: Merck & Company, Inc; 2014.
192. Shaheen NJ, Sharma P, Overholt BF, et al., Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009; 360: 2277-2288.
193. Pouw RE, Wirths K, Eisendrath P, et al., Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010; 8: 23-29.
194. Lin P, Zhang J, Rong Z, et al., Studies on medicamentous inhibitory therapy for esophageal precancerous lesions-3- and 5-year inhibitory effects of antitumor-B, retinamide and riboflavin. Proc Chin Acad Med Sci Peking Union Med Coll. 1990; 5: 121-129.
195. Mark SD, Liu SF, Li JY, et al., The effect of vitamin and mineral supplementation on esophageal cytology: results from the Linxian Dysplasia Trial. Int J Cancer. 1994; 57: 162-166.
196. Wahrendorf J, Munoz N, Lu JB, Thurnham DI, Crespi M, Bosch FX,. Blood, retinol and zinc riboflavin status in relation to precancerous lesions of the esophagus: findings from a vitamin intervention trial in the People's Republic of China. Cancer Res. 1988; 48: 2280-2283.
197. Zaridze D, Evstifeeva T, Boyle P,. Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Ann Epidemiol. 1993; 3: 225-234.
198. Stoner GD, Wang LS, Chen T,. Chemoprevention of esophageal squamous cell carcinoma. Toxicol Appl Pharmacol. 2007; 224: 337-349.
199. Brown LM, Devesa SS, Chow WH,. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008; 100: 1184-1187.
200. Shar AO, Gaudard MA, Heath EI, Forastiere AA, Yang VW, Sontag SJ,. Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus. Contemp Clin Trials. 2009; 30: 2-7.
201. Das D, Chilton AP, Jankowski JA,. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009; 181: 161-169.
202. Janakiram NB, Rao CV,. The role of inflammation in colon cancer. Adv Exp Med Biol. 2014; 816: 25-52.
203. Corpet DE, Tache S,. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer. 2002; 43: 1-21.
204. Shpitz B, Klein E, Buklan G, et al., Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut. 2003; 52: 1598-1601.
205. Takayama T, Katsuki S, Takahashi Y, et al., Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 1998; 339: 1277-1284.
206. Zauber AG, Winawer SJ, O'Brien MJ, et al., Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012; 366: 687-696.
207. Liao X, Lochhead P, Nishihara R, et al., Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012; 367: 1596-1606.
208. Guda K, Fink SP, Milne GL, et al., Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance. Cancer Prev Res (Phila). 2014; 7: 805-812.
209. Solomon SD, Wittes J, Finn PV, et al., Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008; 117: 2104-2113.
210. Bertagnolli MM, Eagle CJ, Zauber AG, et al., Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009; 2: 310-321.
211. Ladenheim J, Garcia G, Titzer D, et al., Effect of sulindac on sporadic colonic polyps. Gastroenterology. 1995; 108: 1083-1087.
212. Bhala N, Emberson J, Merhi A, et al., Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382: 769-779.
213. De Petris G, Lõpez JI,. Histopathology of diaphragm disease of the small intestine: a study of 10 cases from a single institution. Am J Clin Pathol. 2008; 130: 518-525.
214. Lang J, Price AB, Levi AJ, Burke M, Gumpel JM, Bjarnason I,. Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. J Clin Pathol. 1988; 41: 516-526.
215. Maiden L, Thjodleifsson B, Seigal A, et al., Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007; 5: 1040-1045.
216. US Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2007; 146: 361-364.
217. Nigro ND, Bull AW, Wilson PS, Soullier BK, Alousi MA,. Combined inhibitors of carcinogenesis: effect on azoxymethane-induced intestinal cancer in rats. J Natl Cancer Inst. 1982; 69: 103-107.
218. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G,. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res. 1990; 50: 2562-2568.
219. Farraye FA, Odze RD, Eaden J, Itzkowitz SH,. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010; 138: 746-774, 774.e1-774.e4; quiz 774.e12-774.e13.
220. Zhao LN, Li JY, Yu T, Chen GC, Yuan YH, Chen QK,. 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis [serial online]. PLoS One. 2014; 9: e94208.
221. Velayos FS, Terdiman JP, Walsh JM,. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2005; 100: 1345-1353.
222. Nguyen GC, Gulamhusein A, Bernstein CN,. 5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol. 2012; 107: 1298-1304; quiz 1297, 1305.
223. Hansen JD, Kumar S, Lo WK, Poulsen DM, Halai UA, Tater KC,. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. Dig Dis Sci. 2013; 58: 3079-3087.
224. Singh S, Khanna S, Pardi DS, Loftus EV Jr, Talwalkar JA,. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013; 19: 1631-1638.
225. Eaton JE, Silveira MG, Pardi DS, et al., High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011; 106: 1638-1645.
226. Smith A, Balar AV, Milowsky MI, Chen RC,. Chapter 83. Bladder cancer. In:, Niederhuber JE, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff's Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier; 2014: 1445-1462.
227. Morales A, Eidinger D, Bruce AW,. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976; 116: 180-183.
228. Ehdaie B, Sylvester R, Herr HW,. Maintenance bacillus Calmette-Guerin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol. 2013; 64: 579-585.
229. American Cancer Society. Cancer Facts & Figures 2015. cancer.org/research/cancerfactsstatistics
230. Karia PS, Han J, Schmults CD,. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013; 68: 957-966.
231. Frost CA, Green AC,. Epidemiology of solar keratoses. Br J Dermatol. 1994; 131: 455-464.
232. Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB Jr, Feldman SR,. Frequency and cost of actinic keratosis treatment. Dermatol Surg. 2006; 32: 1045-1049.
233. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF,. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009; 115: 2523-2530.
234. Rigel DS, Stein Gold LF,. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol. 2013; 68: S20-S27.
235. Gupta AK, Paquet M, Villanueva E, Brintnell W,. Interventions for actinic keratoses [serial online]. Cochrane Database Syst Rev. 2012; 12: CD004415.
236. Clouser MC, Roe DJ, Foote JA, Harris RB, Alberts DS,. Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. Nutr Cancer. 2010; 62: 1058-1066.
237. Elmets CA, Viner JL, Pentland AP, et al., Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010; 102: 1835-1844.
238. Gurpinar E, Grizzle WE, Piazza GA,. NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res. 2014; 20: 1104-1113.
239. Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, Sterry W, Stockfleth E,. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol. 2010; 20: 482-488.
240. Kreul SM, Havighurst T, Kim K, et al., A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res (Phila). 2012; 5: 1368-1374.
241. Sekulic A, Migden MR, Oro AE, et al., Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366: 2171-2179.
242. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics. CA Cancer J Clin. 2014; 64: 9-29.
243. Marks R, Dorevitch AP, Mason G,. Do all melanomas come from "moles?" A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol. 1990; 31: 77-80.
244. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H,. Cutaneous melanomas associated with nevi. Arch Dermatol. 2003; 139: 1620-1624; discussion 1624.
245. Goodman JR, Grossman D,. Aspirin and other NSAIDs as chemoprevention agents in melanoma. Cancer Prev Res (Phila). 2014; 7: 557-564.
246. Uzarska M, Czajkowski R, Schwartz RA, Bajek A, Zegarska B, Drewa T,. Chemoprevention of skin melanoma: facts and myths. Melanoma Res. 2013; 23: 426-433.
247. Linden KG, Leachman SA, Zager JS, et al., A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology. Cancer Prev Res (Phila). 2014; 7: 496-504.
248. Curiel-Lewandrowski C, Swetter SM, Einspahr JG, et al., Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. Cancer. 2012; 118: 5848-5856.
249. Agrawal N, Frederick MJ, Pickering CR, et al., Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011; 333: 1154-1157.
250. Pickering CR, Zhou JH, Lee JJ, et al., Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014; 20: 6582-6592.
251. Wang NJ, Sanborn Z, Arnett KL, et al., Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A. 2011; 108: 17761-17766.
252. South AP, Purdie KJ, Watt SA, et al., NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol. 2014; 134: 2630-2638.
253. Stransky N, Egloff AM, Tward AD, et al., The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333: 1157-1160.
254. Durinck S, Ho C, Wang NJ, et al., Temporal dissection of tumorigenesis in primary cancers. Cancer Discov. 2011; 1: 137-143.
255. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489: 519-525.
256. Bass AJ, Watanabe H, Mermel CH, et al., SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009; 41: 1238-1242.
257. Lippman SM, Lee JJ, Martin JW, et al., Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res. 2006; 12: 3109-3114.
258. William WN Jr, Lee JJ, Lippman SM, et al., High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009; 2: 22-26.
259. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315:1501-1505.
260. Papadimitrakopoulou V, Izzo JG, Liu DD, et al., Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009; 2: 14-21.
261. Saintigny P, Zhang L, Fan YH, et al., Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011; 4: 218-229.
262. Taoudi Benchekroun M, Saintigny P, Thomas SM, et al., Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila). 2010; 3: 800-809.
263. Mao L, Lee JS, Fan YH, et al., Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 1996; 2: 682-685.
264. Zhang L, Poh CF, Williams M, et al., Loss of heterozygosity (LOH) profiles-validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila). 2012; 5: 1081-1089.
265. William WN Jr, Heymach JV, Kim ES, Lippman SM,. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov. 2009; 8: 213-225.
266. William WN, Papadimitrakopoulou V, Lee JJ, et al., Randomized placebo controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC) [abstract]. J Clin Oncol. 2014; 32: 5s. Abstract 6007.
267. D'Souza G, Cullen K, Bowie J, Thorpe R, Fakhry C,. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection [serial online]. PLoS One. 2014; 9: e86023.
268. Herrero R, Quint W, Hildesheim A, et al., Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica [serial online]. PLoS One. 2013; 8: e68329.
269. Lee JJ, Wu X, Hildebrandt MA, et al., Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila). 2011; 4: 185-193.
270. Hecht SS, Szabo E,. Fifty years of tobacco carcinogenesis research: from mechanisms to early detection and prevention of lung cancer. Cancer Prev Res (Phila). 2014; 7: 1-8.
271. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK,. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14: 535-546.
272. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE,. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005; 142: 233-239.
273. Auerbach O, Stout AP, Hammond EC, Garfinkel L,. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med. 1961; 265: 253-267.
274. Saccomanno G, Archer VE, Auerbach O, Saunders RP, Brennan LM,. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer. 1974; 33: 256-270.
275. Szabo E, Mao JT, Lam S, Reid ME, Keith RL,. Chemoprevention of lung cancer: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5 suppl): e40S-e60S.
276. De Luca LM, Ross SA,. Beta-carotene increases lung cancer incidence in cigarette smokers. Nutr Rev. 1996; 54: 178-180.
277. Meyskens FL Jr, Szabo E,. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1366-1369.
278. Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall JR,. Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev. 2002; 11: 1285-1291.
279. Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, Meade TW,. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377: 31-41.
280. Veronesi G, Szabo E, Decensi A, et al., Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila). 2011; 4: 34-42.
281. Hoadley KA, Yau C, Wolf DM, et al., Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014; 158: 929-944.
282. Gustafson AM, Soldi R, Anderlind C, et al., Airway PI3K pathway activation is an early and reversible event in lung cancer development [serial online]. Sci Transl Med. 2010; 2: 26ra25.
283. McWilliams A, Tammemagi MC, Mayo JR, et al., Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013; 369: 910-919.
284. Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R,. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011; 365: 97-99.
285. Lucia MS, Epstein JI, Goodman PJ, et al., Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007; 99: 1375-1383.
286. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM,. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila). 2008; 1: 174-181.
287. Thompson IM Jr, Goodman PJ, Tangen CM, et al., Long-term survival of participants in the Prostate Cancer Prevention Trial. N Engl J Med. 2013; 369: 603-610.
288. Kristal AR, Darke AK, Morris JS, et al., Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk [serial online]. J Natl Cancer Inst. 2014; 106: djt456.
289. Chen HL, Chang MH, Ni YH, et al., Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA. 1996; 276: 906-908.
290. Chang MH, Chen CJ, Lai MS, et al., Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997; 336: 1855-1859.
291. Chang MH, Shau WY, Chen CJ, et al., Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000; 284: 3040-3042.
292. Lee CL, Hsieh KS, Ko YC,. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev. 2003; 12: 57-59.
293. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ,. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013; 310: 974-976.
294. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH,. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000; 132: 296-305.
295. Park SH, Rehermann B,. Immune responses to HCV and other hepatitis viruses. Immunity. 2014; 40: 13-24.
296. Moyer VA,. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013; 159: 349-357.
297. LeFevre ML,. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 161: 58-66.
298. Mazzella G, Saracco G, Festi D, et al., Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol. 1999; 94: 2246-2250.
299. Lampertico P, Del Ninno E, Manzin A, et al., A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997; 26: 1621-1625.
300. Chan HL, Wang H, Niu J, Chim AM, Sung JJ,. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007; 12: 345-353.
301. Smith BD, Morgan RL, Beckett GA, et al., Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012; 61 (RR-4): 1-32.
302. Parkin DM,. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 3030-3044.
303. Sung JJ, Lin SR, Ching JY, et al., Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000; 119: 7-14.
304. Leung WK, Lin SR, Ching JY, et al., Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut. 2004; 53: 1244-1249.
305. Saito D, Boku N, Fujioka T, et al., Impact of H pylori eradication on gastric cancer prevention: endoscopic results of the Japanese intervention trial (JITHP-Study): a randomized multi-center trial [abstract]. Gastroenterology. 2005; 128 (suppl 2): A4.
306. Fukase K, Kato M, Kikuchi S, et al., Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008; 372: 392-397.
307. Li WQ, Ma JL, Zhang L, et al., Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups [serial online]. J Natl Cancer Inst. 2014; 106: dju116.
308. Fock KM, Talley N, Moayyedi P, et al., Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol. 2008; 23: 351-365.
309. Dawsey SM, Mark SD, Taylor PR, Limburg PJ,. Gastric cancer and H. pylori. Gut. 2002; 51: 457-458.
310. Kamangar F, Dawsey SM, Blaser MJ, et al., Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 2006; 98: 1445-1452.
311. Hansen S, Melby KK, Aase S, Jellum E, Vollset SE,. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand J Gastroenterol. 1999; 34: 353-360.
312. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001; 49: 347-353.
313. Cavaleiro-Pinto M, Peleteiro B, Lunet N, Barros H,. Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis. Cancer Causes Control. 2011; 22: 375-387.
314. Potter JD,. The failure of cancer chemoprevention. Carcinogenesis. 2014; 35: 974-982.
315. Liby KT, Sporn MB,. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev. 2012; 64: 972-1003.
316. Zhang L, Ren X, Alt E, et al., Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature. 2010; 464: 1058-1061.